DR.REDDY'S LABORATORIES LTD. - 500124 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 201514-10-2024
14-10-2024
Dr Reddy's F&O contract adjustments
The stock split will lead to necessary adjustments in the futures and options (F&O) contracts on this stock on the record date12-10-2024
DR.REDDY'S LABORATORIES LTD. - 500124 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issue of Letter of confirmation in lieu of share certificate(s) reported lost/ misplaced11-10-2024
DR.REDDY'S LABORATORIES LTD. - 500124 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 201510-10-2024
DR.REDDY'S LABORATORIES LTD. - 500124 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 201807-10-2024
DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Acquisition
Incorporation of step down wholly-owned subsidiary05-10-2024
DR.REDDY'S LABORATORIES LTD. - 500124 - Fixation Of Record Date For Sub-Division / Split Of The Equity Shares Of The Company Pursuant To Regulation 42 Of The SEBI (LODR) Regulations, 2015
Fixation of Record date for Sub-division / split of the Equity shares of the Company pursuant to Regulation 42 of the SEBI (LODR) Regulations, 201504-10-2024
Dr Reddy's ties up with Gilead to manufacture, commercialise HIV drug
Dr Reddy's Laboratories on Wednesday said it has tied up with Gilead Sciences for the manufacture and commercialisation of the HIV drug Lenacapavir in India and 120 other countries. The company has entered into a royalty-free non-exclusive voluntary licensing agreement with Gilead Sciences Ireland UC for the drug, the Hyderabad-based drug maker said in a statement. Lenacapavir is a US Food and Drug Administration (USFDA) approved drug indicated for the treatment of human immunodeficiency virus a type 1 (HIV-1) infection in heavily treatment-experienced adults with multi-drug resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations. Additionally, Lenacapavir is currently under investigation for the prevention of HIV (PrEP) which is yet to be approved globally. Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the US and Europe markets in the year 2022. As per the agreement, Dr Reddy's w02-10-2024